Sign in

GMAB on Nasdaq

GENMAB A/S

GENMAB A/S is a pharmaceutical preparations company, listed on Nasdaq (GMAB).1

$38.05 up 1.16 (3.14%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

$3.7BRevenue, fiscal 20253
$963.0MNet income, fiscal 20253

Compare with Alnylam Pharmaceuticals, Dr. Reddy's Laboratories or Perrigo Company Plc, or pick any stock.

  • TickerGMAB on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • Business addressToldbodgade 33, 1253 Copenhagen K, G7 000004
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

These forward-looking statements include, but are not limited to, statements about:5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

28.6%Operating margin3
25.9%Net margin3
19.2%Revenue growth, 20253
16.5%Return on equity3
0.86×Debt to equity3
$1.1BFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

Denmark brought in 89% of the revenue GENMAB A/S broke down this way in fiscal 2025.

  1. Denmark$3.3B389%up 16% from 2024
  2. Japan$213.0M36%up 75% from 2024
  3. United States$180.0M35%up 37% from 2024
  4. Netherlands$1.0M30%
Regions by year
Regions202320242025
Denmark$2.3B$2.9B$3.3B
Japan$6.0M$122.0M$213.0M
United States$55.0M$131.0M$180.0M
Netherlands$0$0$1.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue6¢$238.0M
  • Research and development41¢$1.6B
  • Selling, general and admin16¢$626.0M
  • Interest7¢$269.0M
  • Income tax6¢$241.0M
  • Profit24¢$963.0M

Out of $3.7B in revenue.3

Where each dollar of operating cash went, fiscal 2025

  • Capital spending3¢$37.0M
  • Kept or used elsewhere97¢$1.1B

Out of $1.2B of cash from operations.3

Financial statements

Revenue3$3.7B in 2025+56% since 2023
0$1.0B$2.0B$3.0B$4.0B2023: $2.4B$2.4B20232024: $3.1B$3.1B2024+31%2025: $3.7B$3.7B2025+19%
Operating income3$1.1B in 2025+38% since 2023
0$500.0M$1.0B$1.5B2023: $772.0M$772.0M20232024: $972.0M$972.0M2024+26%2025: $1.1B$1.1B2025+10%
Net income3$963.0M in 2025+53% since 2023
0$500.0M$1.0B$1.5B2023: $631.0M$631.0M20232024: $1.1B$1.1B2024+80%2025: $963.0M$963.0M2025−15%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Revenue$3.7B$3.1B$2.4B
Cost of product sales-$238.0M-$143.0M-$33.0M
Research and development expenses-$1.6B-$1.4B-$1.1B
Selling, general and administrative expenses-$626.0M-$549.0M-$478.0M
Acquisition and integration related charges-$185.0M-$43.0M$0
Total costs and operating expenses-$2.7B-$2.1B-$1.6B
Operating profit$1.1B$972.0M$772.0M
Financial income$408.0M$645.0M$299.0M
Financial expenses-$269.0M-$291.0M-$254.0M
Net profit before tax$1.2B$1.3B$817.0M
Corporate tax-$241.0M-$193.0M-$186.0M
Net profit963.0M DKK7.8B DKK4.4B DKK
Exchange differences on translation of foreign operations$45.0M-$224.0M$139.0M
Total comprehensive income1.0B DKK8.3B DKK4.3B DKK
Basic net profit per share (in dollars per share)15.50 DKK122.21 DKK66.64 DKK
Diluted net profit per share (in dollars per share)15.37 DKK121.36 DKK66.02 DKK

Compare GENMAB A/S with another company

Corporate structure

GENMAB A/S sits at the top of its group. 2 entities on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of GENMAB A/S

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

What it owns

What GENMAB A/S reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$153.0M3 Dec 31, 2025$137.0M3 Dec 31, 2024+11.7%
Operating-lease assets (leased space)$127.0M3 Dec 31, 2025$128.0M3 Dec 31, 2024−0.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.7B3 Dec 31, 2025$1.4B3 Dec 31, 2024+24.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$355.0M3 Dec 31, 2025$355.0M3 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$9.1B3 Dec 31, 2025$1.7B3 Dec 31, 2024+428.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$18.0M3 Dec 31, 2025$9.0M3 Dec 31, 2024+100.0%

Calendar

Coming up

  1. Nov 5, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.65 a share, on Nov 6, 2025.6

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

358 filings to the SEC since October 2021: 5 annual reports, 11 large holders, 342 other. The latest 20:

  1. Oct 13, 20266-K EDGAR
  2. Oct 7, 20266-K EDGAR
  3. Oct 5, 20266-K EDGAR
  4. Oct 5, 2026SCHEDULE 13G EDGAR
  5. Oct 2, 20266-K EDGAR
  6. Sep 29, 20266-K EDGAR
  7. Sep 24, 20266-K EDGAR
  8. Sep 9, 20266-K EDGAR
  9. Sep 9, 20266-K EDGAR
  10. Sep 8, 20266-K EDGAR
  11. Aug 14, 2026SCHEDULE 13G/A EDGAR
  12. Aug 12, 20266-K EDGAR
  13. Aug 11, 20266-K EDGAR
  14. Aug 6, 20266-K EDGAR
  15. Jul 15, 20266-K EDGAR
  16. Jun 29, 20266-K EDGAR
  17. Jun 17, 20266-K EDGAR
  18. Jun 16, 20266-K EDGAR
  19. Jun 15, 20266-K EDGAR
  20. Jun 15, 20266-K EDGAR

The 358 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

GENMAB A/S has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Paradigm Biocapital Advisors LP13,133,131$360.8M6.8%+5,165,295
Orbis Allan Gray Ltd11,368,161$312.3M1.1%−1,557,417
Alliancebernstein L.P.8,644,877$231.9M0.1%−912,272
Deerfield Management Company, L.P.6,865,000$188.6M2.3%+4,403,000
Deep Track Capital, LP5,650,000$155.2M2.3%+1,986,750
Arrowstreet Capital, Limited Partnership4,975,324$136.7M0.1%No change
BlackRock, Inc.4,671,252$128.3M0.0%+134,687
Sofinnova Investments, Inc.4,045,215$111.1M5.9%+3,292,954
Renaissance Technologies LLC3,517,850$96.6M0.1%−896,700
Two Sigma Investments, LP3,506,843$96.3M0.1%+1,167,411
Harding Loevner LP3,086,318$86.9M0.8%−145,283
First Trust Advisors LP2,756,522$75.7M0.0%+295,180
Citadel Advisors LLC2,475,991$68.0M0.0%New
Qube Research & Technologies Ltd1,689,284$46.4M0.1%+1,011,938
Morgan Stanley1,630,161$44.8M0.0%−554,540
Federated Hermes, Inc.1,449,376$39.8M0.1%+197,786
Goldman Sachs Group Inc1,279,231$35.1M0.0%+347,972
Franklin Resources Inc1,202,923$33.0M0.0%+9,778
Pictet Asset Management Holding SA1,065,927$29.3M0.0%−11,544
UBS Group AG961,053$26.4M0.0%+662,921
Perpetual Ltd919,048$25.2M0.4%+160,545
Northern Trust Corp916,600$25.2M0.0%−33,934
Millennium Management LLC910,604$25.0M0.0%+118,311
Russell Investments Group, Ltd.883,430$24.3M0.0%+86,362
Envestnet Asset Management Inc829,687$22.8M0.0%−32,614

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

12 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 30, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000+24.3%Report
Jan 16, 2025Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000+47.8%Report
Dec 16, 2024Josh GottheimerDemocratic, HouseSale$1,001 - $15,000−61.7%Report
Jul 19, 2024Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−4.3%Report
Jun 18, 2024Josh GottheimerDemocratic, HouseSale$1,001 - $15,000−5.9%Report
Oct 16, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−60.8%Report
Sep 15, 2023Josh GottheimerDemocratic, HouseSale$1,001 - $15,000+74.5%Report
Jul 20, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−79.4%Report
Jul 19, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−77.1%Report
Jul 10, 2023Daniel S. GoldmanDemocratic, HouseSale$50,001 - $100,000+75.6%Report
Mar 31, 2023Daniel S. GoldmanDemocratic, HousePartial sale$1,001 - $15,000+88.4%Report
Nov 20, 2020Thomas R Carper, SenateBuy$1,001 - $15,000−113.7%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How GENMAB A/S is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGENMAB A/S1
  • CIK0001434265
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company5
  • Incorporated inThe Kingdom of Denmark5
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressToldbodgade 33, 1253 Copenhagen K, G7 000001
  • Phone+45 7020 27285
  • Shares outstanding64,238,408 shares; 64,377,450 shares5
  • On EDGAR sinceApr 28, 20081
  • Filings563 in all: 6-K (483), 20-F (7), S-8 (6), SC 13G/A (5), 4 (4), F-6EF (4), SC TO-T/A (4), SCHEDULE 13G/A (4)1
    All 36 form types

    CORRESP (3), EFFECT (3), FWP (3), UPLOAD (3), 144 (2), ARS (2), DRS/A (2), DRSLTR (2), F-1/A (2), F-6 (2), F-6 POS (2), SC 13G (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 12G3-2B (1), 3 (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1MEF (1), SC TO-C (1), SC TO-T (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1), SUPPL (1)

  • Latest filingsAnnual report (20-F) Feb 17, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing one-tenth of one ordinary shareGMABNasdaq
Ordinary shares, nominal value DKK 1 per shareGMABNasdaq

From the cover page of the 20-F filed Feb 17, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceGMAB quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11